DK1470815T3 - Opioidformulering til smertebehandling - Google Patents

Opioidformulering til smertebehandling

Info

Publication number
DK1470815T3
DK1470815T3 DK04009845T DK04009845T DK1470815T3 DK 1470815 T3 DK1470815 T3 DK 1470815T3 DK 04009845 T DK04009845 T DK 04009845T DK 04009845 T DK04009845 T DK 04009845T DK 1470815 T3 DK1470815 T3 DK 1470815T3
Authority
DK
Denmark
Prior art keywords
dose
opioid analgesic
formulation
opioid
patient
Prior art date
Application number
DK04009845T
Other languages
Danish (da)
English (en)
Inventor
Richard Sackler
Paul Goldenheim
Robert Kaiko
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22559696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1470815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1470815T3 publication Critical patent/DK1470815T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
DK04009845T 1993-11-23 1994-11-22 Opioidformulering til smertebehandling DK1470815T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/156,468 US5478577A (en) 1993-11-23 1993-11-23 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
PCT/US1994/013606 WO1995014460A1 (en) 1993-11-23 1994-11-22 Opioid formulations for treating pain

Publications (1)

Publication Number Publication Date
DK1470815T3 true DK1470815T3 (da) 2006-10-02

Family

ID=22559696

Family Applications (3)

Application Number Title Priority Date Filing Date
DK00107670T DK1023896T3 (da) 1993-11-23 1994-11-22 Opoidformuleringer til behandling af smerter
DK04009845T DK1470815T3 (da) 1993-11-23 1994-11-22 Opioidformulering til smertebehandling
DK95904755T DK0731694T4 (da) 1993-11-23 1994-11-22 Opioidformuleringer til behandling af smerter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00107670T DK1023896T3 (da) 1993-11-23 1994-11-22 Opoidformuleringer til behandling af smerter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95904755T DK0731694T4 (da) 1993-11-23 1994-11-22 Opioidformuleringer til behandling af smerter

Country Status (23)

Country Link
US (10) US5478577A (ja)
EP (4) EP1023896B1 (ja)
JP (5) JPH09505602A (ja)
KR (1) KR100201767B1 (ja)
CN (1) CN1134253C (ja)
AT (3) ATE212831T1 (ja)
AU (1) AU693134B2 (ja)
BG (1) BG63269B1 (ja)
CZ (1) CZ292936B6 (ja)
DE (3) DE69429826T3 (ja)
DK (3) DK1023896T3 (ja)
ES (3) ES2266951T3 (ja)
FI (1) FI121588B (ja)
HK (1) HK1029927A1 (ja)
HU (1) HUT73976A (ja)
IL (1) IL111742A (ja)
NO (1) NO315147B1 (ja)
NZ (3) NZ277917A (ja)
PL (1) PL312587A1 (ja)
PT (3) PT1023896E (ja)
SK (1) SK283544B6 (ja)
TW (1) TW420617B (ja)
WO (1) WO1995014460A1 (ja)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5693669A (en) * 1992-10-26 1997-12-02 Godecke Aktiengesellschaft Tilidine dihydrogen orthophosphate, method of preparing it and pharmaceutical preparation containing it
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
SE9301057L (sv) † 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) * 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP0672416A1 (en) * 1994-03-14 1995-09-20 Euro-Celtique S.A. Pharmaceutical composition comprising diamorphine
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
CA2223768A1 (en) * 1995-06-09 1996-12-27 R.P. Scherer Corporation Suspension and soft gelatin capsules containing particulate matter
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
EP0871445A4 (en) * 1995-12-07 2001-01-10 Lilly Co Eli COMPOSITION FOR TREATING PAIN
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AU2021997A (en) * 1996-03-08 1997-09-22 Nycomed Danmark A/S Modified release multiple-units dosage composition
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
BE1010803A3 (fr) * 1996-12-16 1999-02-02 Therabel Research Sa Comprimes pharmaceutiques a liberation prolongee a base de tramadol et leur preparation.
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
DK1009387T3 (da) * 1997-07-02 2006-08-14 Euro Celtique Sa Stabiliserede tramadolformuleringer med langvarig frigivelse
WO1999012524A1 (en) * 1997-09-11 1999-03-18 Nycomed Danmark A/S MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
TW477702B (en) 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
EP0928610A1 (en) * 1998-01-08 1999-07-14 Development Center For Biotechnology Controlled release tacrine dosage form
FR2774910B1 (fr) 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
CA2321924A1 (en) * 1998-02-25 1999-09-02 Abbott Laboratories Butorphanol sustained release formulations
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
ES2221370T3 (es) * 1998-04-03 2004-12-16 Egalet A/S Composicion de liberacion controlada.
CO5070568A1 (es) 1998-05-22 2001-08-28 Eurand Internatrional Spa Proceso de aplicacion de capas y aparato para efectuarlo
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
AU765496C (en) * 1999-08-27 2005-08-25 Brookwood Pharmaceuticals Inc. Injectable buprenorphine microparticle compositions and their use
MXPA02002193A (es) * 1999-08-31 2002-09-30 Gr Nenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
EP2305218A1 (en) * 1999-10-29 2011-04-06 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) * 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN100563656C (zh) 2000-02-08 2009-12-02 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
AU2002305559B2 (en) 2001-05-11 2008-04-03 Mundipharma Pty Limited Abuse-resistant controlled-release opioid dosage form
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
WO2003004029A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
BR0205721A (pt) * 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
JP4504013B2 (ja) 2001-08-06 2010-07-14 ユーロ−セルティーク エス．エイ． 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
EP1429739A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
NL1021822C2 (nl) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosinetabletten.
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
ES2627300T3 (es) 2002-04-05 2017-07-27 Mundipharma Pharmaceuticals S.L. Preparación farmacéutica que contiene oxicodona y naloxona
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
MXPA04010769A (es) * 2002-04-29 2005-07-05 Alza Corp Metodos y formas de dosificacion para suministro controlado de oxicodona.
NZ536965A (en) 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
RU2004134728A (ru) * 2002-05-31 2005-06-10 Алза Корпорейшн (Us) Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
EP2218448B1 (en) * 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
DE10300325A1 (de) 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
EP1905435A3 (en) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE602004014747D1 (de) * 2003-03-26 2008-08-14 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ES2360102T3 (es) * 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
CN102772357B (zh) 2003-03-31 2014-12-31 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP5501553B2 (ja) * 2003-04-21 2014-05-21 ユーロ−セルティーク エス．エイ． 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
JP5670609B2 (ja) * 2003-09-26 2015-02-18 アルザ・コーポレーシヨン 有効成分の制御送達のためのｏｒｏｓプッシュ−スティック
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
MXPA06003454A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada de analgesicos opioides y no opiodes.
CA2874604A1 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
DK1729730T3 (da) * 2004-03-30 2009-03-23 Euro Celtique Sa Manipulationssikker doseringsform, der omfatter et adsorberende stof og et kontramiddel
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06011871A (es) * 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
KR20080046751A (ko) * 2004-09-01 2008-05-27 유로-셀띠끄 소시에떼 아노님 용량 비례적 정상 상태 Ｃａｖｅ및 ＡＵＣ를 갖고, 용량비례적 단일 용량 Ｃｍａｘ보다 작은 오피오이드성 제형
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR20070087643A (ko) * 2004-12-09 2007-08-28 셀진 코포레이션 Ｄ-트레오 메틸페니데이트를 이용한 치료
TWI432196B (zh) * 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP2319499A1 (en) * 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1895989A2 (en) * 2005-06-03 2008-03-12 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
KR20080032209A (ko) 2005-07-20 2008-04-14 파나세아 바이오테크 리미티드 사이클로옥시지네이즈 효소 억제제를 구성하는 새로운형태의 약학적 변형된 용출 용량형 조성물
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
NZ592836A (en) 2005-07-27 2013-01-25 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
PT2402005T (pt) 2005-08-24 2021-04-14 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
EP1959966B1 (en) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
FR2894143B1 (fr) 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
EP1810678A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2081550B2 (en) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
ES2622576T3 (es) 2006-06-19 2017-07-06 Alpharma Pharmaceuticals Llc Composiciones farmacéuticas
PT2046300E (pt) * 2006-08-04 2010-07-01 Ethypharm Sa Comprimido multicamadas de desintegraã†o oral
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
JP5489719B2 (ja) 2006-11-17 2014-05-14 スパーナス ファーマシューティカルズ インコーポレイテッド トピラマートの徐放性配合物
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
US20080131501A1 (en) * 2006-12-04 2008-06-05 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
MX336789B (es) * 2007-08-13 2016-02-02 Inspirion Delivery Technologies Llc Farmacos resistentes al abuso, metodo de uso y metodo de fabricacion.
CA2678092C (en) * 2007-10-16 2013-07-30 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
MX2011002836A (es) 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
BRPI0923836A2 (pt) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Composições farmacêuticas orais contendo opióide e métodos
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
LT2405915T (lt) 2009-03-10 2019-03-12 Euro-Celtique S.A. Greito atpalaidavimo farmacinė kompozicija, apimanti oksikodoną ir naloksoną
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
NZ598922A (en) * 2009-08-31 2014-03-28 Depomed Inc Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
JP5819680B2 (ja) * 2010-09-03 2015-11-24 帝人ファーマ株式会社 塩酸アンブロキソールの小型徐放性製剤
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN110101702A (zh) 2012-04-17 2019-08-09 普渡制药公司 用于治疗阿片样物质所致不良药效学响应的系统和方法
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
AU2014215478B2 (en) 2013-02-05 2018-09-13 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP2799009A1 (en) * 2013-04-29 2014-11-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Non-invasive method for prediction of opioid-analgesia and opioid-blood-concentrations
EP3004115B1 (en) 2013-05-24 2019-03-06 Rhodes Technologies Opioid ketal compounds and uses thereof
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
CN109715151A (zh) 2016-08-11 2019-05-03 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
CN106266068A (zh) * 2016-09-18 2017-01-04 遵义师范学院 一种速释‑缓控释型对坐叶微丸胶囊及其制备方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3755704A1 (en) 2018-02-23 2020-12-30 Rhodes Technologies Inc. Novel opioid compounds and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2806033A (en) * 1955-08-03 1957-09-10 Lewenstein Morphine derivative
IL26896A (en) * 1966-01-19 1970-11-30 Endo Lab 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3684584A (en) * 1971-03-15 1972-08-15 Driver Co Wilbur B Thermocouple extension wire
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4162753A (en) * 1978-07-13 1979-07-31 Brown William R Necktie hanger
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
AU1873783A (en) * 1982-10-08 1984-04-12 Verex Laboratories Inc. Constant release formulation
US4466646A (en) * 1983-02-25 1984-08-21 General Motors Corporation Energy absorbing bumper assembly for vehicles
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
ATE84713T1 (de) * 1985-05-13 1993-02-15 Miles Inc Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome.
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE107857T1 (de) † 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) † 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
JP2643222B2 (ja) † 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
DK161743C (da) * 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
JPH03163030A (ja) * 1989-08-28 1991-07-15 Arizona Technol Dev Corp アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5198203A (en) * 1990-01-25 1993-03-30 Mobil Oil Corp. Synthetic mesoporous crystalline material
WO1992001446A1 (en) * 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
DK0472502T3 (da) * 1990-08-24 1995-10-09 Spirig Ag Fremgangsmåde til fremstilling af pellets
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
HU217584B (hu) * 1991-09-06 2000-02-28 Mcneilab Inc. Egy tramadolszármazékot és kodeint, oxikodont vagy hidrokodont tartalmazó szinergetikus gyógyászati készítmények, és eljárás előállításukra
SG80535A1 (en) * 1991-09-06 2001-05-22 Mcneilab Inc Composition comprising a tramadol material and acetaminophen and its use
US5223541A (en) * 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5226331A (en) * 1991-10-03 1993-07-13 General Electric Company Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
GB9121204D0 (en) * 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
AU5160893A (en) * 1992-10-16 1994-05-09 Nippon Shinyaku Co. Ltd. Method of manufacturing wax matrices
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
DE4315525B4 (de) † 1993-05-10 2010-04-15 Euro-Celtique S.A. Pharmazeutische Zusammensetzung
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5358269A (en) * 1993-08-30 1994-10-25 Jakeman Walter L Trailer hitch
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
EP2036558A3 (en) * 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5716631A (en) * 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6085954A (en) * 1998-07-15 2000-07-11 Graber Products, Inc. Pivoting extensible rear hitch attachment for equipment carrier
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
US6736434B2 (en) * 2000-03-22 2004-05-18 Meridian Automotive Systems, Inc. Vehicle and bumper assembly therefor having an integral fascia and energy absorber, and method for making the same
BR0205721A (pt) * 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
WO2003004029A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
JP2005523876A (ja) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤

Also Published As

Publication number Publication date
EP0731694B1 (en) 2002-02-06
US20070237832A1 (en) 2007-10-11
ATE212831T1 (de) 2002-02-15
BG63269B1 (bg) 2001-08-31
DE69429826T3 (de) 2006-08-03
DE69434911D1 (de) 2007-02-15
FI121588B (fi) 2011-01-31
CN1130352A (zh) 1996-09-04
US20020058050A1 (en) 2002-05-16
JP2009102376A (ja) 2009-05-14
PT731694E (pt) 2002-06-28
PT1470815E (pt) 2006-09-29
ATE327739T1 (de) 2006-06-15
WO1995014460A1 (en) 1995-06-01
JP4425093B2 (ja) 2010-03-03
ES2279742T3 (es) 2007-09-01
ATE350022T1 (de) 2007-01-15
DE69429826T2 (de) 2002-09-05
DK0731694T4 (da) 2005-12-19
NZ508526A (en) 2004-12-24
EP0731694A1 (en) 1996-09-18
KR960703004A (ko) 1996-06-19
CN1134253C (zh) 2004-01-14
JP2004323536A (ja) 2004-11-18
BG100346A (bg) 1996-07-31
SK283544B6 (sk) 2003-09-11
SK153895A3 (en) 1996-06-05
JPH09505602A (ja) 1997-06-03
EP1023896A9 (en) 2007-05-23
HU9503468D0 (en) 1996-01-29
DE69434752D1 (de) 2006-07-06
JP4368562B2 (ja) 2009-11-18
JP2006290901A (ja) 2006-10-26
NO954925L (no) 1996-05-23
NZ277917A (en) 1998-04-27
DK0731694T3 (da) 2002-05-13
NZ336055A (en) 2001-01-26
US20080031963A1 (en) 2008-02-07
DE69434911T2 (de) 2007-08-30
DK1023896T3 (da) 2007-05-14
US20070237833A1 (en) 2007-10-11
TW420617B (en) 2001-02-01
US20060269604A1 (en) 2006-11-30
IL111742A (en) 2004-02-19
US20030035837A1 (en) 2003-02-20
EP1776950A1 (en) 2007-04-25
DE69434752T2 (de) 2007-05-16
AU693134B2 (en) 1998-06-25
AU1331395A (en) 1995-06-13
EP1470815A1 (en) 2004-10-27
JP2002371015A (ja) 2002-12-26
NO954925D0 (no) 1995-12-05
KR100201767B1 (ko) 1999-06-15
EP0731694A4 (ja) 1996-10-02
US5478577A (en) 1995-12-26
HUT73976A (en) 1996-10-28
DE69429826D1 (de) 2002-03-21
CZ321795A3 (en) 1996-07-17
US5672360A (en) 1997-09-30
FI955782A (fi) 1996-01-30
NO315147B1 (no) 2003-07-21
JP4908527B2 (ja) 2012-04-04
PL312587A1 (en) 1996-04-29
EP1023896B1 (en) 2007-01-03
HK1029927A1 (en) 2001-04-20
US20100209351A1 (en) 2010-08-19
FI955782A0 (fi) 1995-12-01
JP4767772B2 (ja) 2011-09-07
EP1470815B1 (en) 2006-05-31
EP0731694B2 (en) 2005-09-07
EP1023896A2 (en) 2000-08-02
CZ292936B6 (cs) 2004-01-14
ES2266951T3 (es) 2007-03-01
IL111742A0 (en) 1995-01-24
EP1023896A3 (en) 2003-05-02
US20100209514A1 (en) 2010-08-19
PT1023896E (pt) 2007-03-30
ES2170136T5 (es) 2006-04-01
ES2170136T3 (es) 2002-08-01

Similar Documents

Publication Publication Date Title
DK1470815T3 (da) Opioidformulering til smertebehandling
CA2276170A1 (en) Sustained analgesia achieved with buprenorphine
NO972780D0 (no) Inhalasjonsanordning, fremgangsmåte for fordeling av et farmasöytisk aktivt stoff og fremgangsmåte for administrering av en dose med et farmasöytisk aktivt stoff
ATE292982T1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
NO944565D0 (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
PT957899E (pt) Forma de dosagem para proporcionar um medicamento numa dose crescente
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
AU2313297A (en) Transdermally administered dextromethorphan as antitussive agent
US6143320A (en) Method for the application of an active substance patch for controlling or alleviating an addiction
WO2002047688A3 (en) Method and apparatus for treating breakthrough pain
SE9101341D0 (sv) New medicinal use
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
RU2000111645A (ru) Способ лечения геморрагической лихорадки с почечным синдромом
IL164092A0 (en) The use of devazepide as analgesic agent
UA30654A (uk) Спосіб лікування посттравматичних дисфункцій висково- нижньощелепового суглоба
UA30631A (uk) Спосіб лікування надмірної ваги